Merus N.V. CS (MRUS)

Feb 18, 2025, 8:00 AM EST - 5 days ago

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Feb 13, 2025, 8:00 AM EST - 10 days ago

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

Feb 5, 2025, 5:00 PM EST - 17 days ago

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Jan 20, 2025, 5:08 AM EST - 4 weeks ago

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Jan 12, 2025, 8:04 PM EST - 5 weeks ago

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Dec 16, 2024, 4:01 PM EST - 2 months ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Dec 7, 2024, 1:30 AM EST - 2 months ago

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Dec 5, 2024, 2:49 PM EST - 2 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug

Dec 4, 2024, 4:55 PM EST - 2 months ago

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Dec 4, 2024, 3:48 PM EST - 2 months ago

US FDA approves Merus' therapy to treat lung, pancreatic cancers

Dec 2, 2024, 8:00 AM EST - 2 months ago

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Dec 1, 2024, 11:05 AM EST - 3 months ago

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Nov 6, 2024, 4:01 PM EST - 3 months ago

Merus to Present at Upcoming Investor Conferences

Nov 5, 2024, 1:18 PM EST - 3 months ago

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 5, 2024, 6:30 AM EST - 3 months ago

Merus Receives FDA extension of PDUFA for zenocutuzumab

Oct 31, 2024, 8:08 AM EDT - 4 months ago

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Aug 14, 2024, 5:13 PM EDT - 6 months ago

Merus: Great European Oncology Developer, But Properly Valued

Aug 1, 2024, 4:10 PM EDT - 7 months ago

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Jul 24, 2024, 7:00 AM EDT - 7 months ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Jun 3, 2024, 2:30 PM EDT - 9 months ago

Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

Jun 2, 2024, 12:30 PM EDT - 9 months ago

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

May 29, 2024, 9:30 PM EDT - 9 months ago

Merus Announces Pricing of Upsized Public Offering of Common Shares

May 29, 2024, 8:00 AM EDT - 9 months ago

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 28, 2024, 4:01 PM EDT - 9 months ago

Merus N.V. Announces Proposed Public Offering of Common Shares

May 28, 2024, 7:00 AM EDT - 9 months ago

Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

May 24, 2024, 1:00 PM EDT - 9 months ago

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 23, 2024, 5:00 PM EDT - 9 months ago

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

May 23, 2024, 5:00 PM EDT - 9 months ago

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

May 13, 2024, 8:00 AM EDT - 10 months ago

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

May 8, 2024, 4:15 PM EDT - 10 months ago

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

May 6, 2024, 4:05 PM EDT - 10 months ago

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

Apr 24, 2024, 10:00 AM EDT - 10 months ago

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Apr 8, 2024, 12:00 PM EDT - 11 months ago

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Apr 3, 2024, 1:47 PM EDT - 11 months ago

Under-the-radar biotech bets

CRNX SNDX XBI

Mar 6, 2024, 8:00 AM EST - 1 year ago

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

GILD

Mar 1, 2024, 3:12 PM EST - 1 year ago

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Feb 28, 2024, 4:15 PM EST - 1 year ago

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Jan 31, 2024, 8:00 AM EST - 1 year ago

Merus to Participate in Upcoming Investor Conferences

Dec 18, 2023, 8:57 PM EST - 1 year ago

Merus: (Maybe) Building A Better Bispecific

Dec 2, 2023, 8:40 PM EST - 1 year ago

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

Nov 26, 2023, 11:05 AM EST - 1 year ago

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Nov 2, 2023, 4:12 PM EDT - 1 year ago

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Oct 23, 2023, 7:30 AM EDT - 1 year ago

Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

Oct 15, 2023, 7:58 PM EDT - 1 year ago

Merus Announces Business Update Conference Call

Oct 6, 2023, 9:32 AM EDT - 1 year ago

Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

Aug 30, 2023, 9:22 PM EDT - 1 year ago

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

Aug 9, 2023, 9:53 PM EDT - 1 year ago

Merus Announces Pricing of Public Offering of Common Shares

Aug 7, 2023, 4:26 PM EDT - 1 year ago

Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update

Jul 28, 2023, 8:00 AM EDT - 1 year ago

Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023

Jul 5, 2023, 4:01 PM EDT - 1 year ago

Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration